Sindbis Virus with Anti-OX40 Overcomes the Immunosuppressive Tumor Microenvironment of Low-Immunogenic Tumors.

Sindbis alpha-virus immunotherapy anti-OX40 anti-tumor immunity cancer immunity oncolytic virus anti-OX40 combination therapy

Journal

Molecular therapy oncolytics
ISSN: 2372-7705
Titre abrégé: Mol Ther Oncolytics
Pays: United States
ID NLM: 101666776

Informations de publication

Date de publication:
26 Jun 2020
Historique:
received: 15 04 2020
accepted: 29 04 2020
entrez: 2 6 2020
pubmed: 2 6 2020
medline: 2 6 2020
Statut: epublish

Résumé

Despite remarkable responses to cancer immunotherapy in a subset of patients, many patients remain resistant to therapies. It is now clear that elevated levels of tumor-infiltrating T cells as well as a systemic anti-tumor immune response are requirements for successful immunotherapies. However, the tumor microenvironment imposes an additional resistance mechanism to immunotherapy. We have developed a practical and improved strategy for cancer immunotherapy using an oncolytic virus and anti-OX40. This strategy takes advantage of a preexisting T cell immune repertoire

Identifiants

pubmed: 32478167
doi: 10.1016/j.omto.2020.04.012
pii: S2372-7705(20)30062-0
pmc: PMC7251545
doi:

Types de publication

Journal Article

Langues

eng

Pagination

431-447

Subventions

Organisme : NCI NIH HHS
ID : R44 CA250627
Pays : United States

Informations de copyright

© 2020 The Author(s).

Références

Science. 2016 Oct 28;354(6311):481-484
pubmed: 27708054
J Natl Cancer Inst. 2002 Dec 4;94(23):1790-802
pubmed: 12464651
Front Oncol. 2017 Apr 12;7:68
pubmed: 28447025
Sci Transl Med. 2018 Jan 31;10(426):
pubmed: 29386357
Genome Biol. 2010;11(10):R106
pubmed: 20979621
Curr Immunol Rev. 2005 Jun;1(2):119-137
pubmed: 21037949
Cell. 2017 Jan 26;168(3):487-502.e15
pubmed: 28111070
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Mol Ther Oncolytics. 2018 May 03;9:51-63
pubmed: 29988525
Nat Rev Clin Oncol. 2019 Jul;16(7):425-441
pubmed: 30914826
J Virol. 1993 Nov;67(11):6439-46
pubmed: 8411346
Cell. 2015 Sep 10;162(6):1229-41
pubmed: 26321679
Ann Oncol. 2004 Jun;15(6):988-9
pubmed: 15151960
Parasitol Int. 2012 Mar;61(1):124-9
pubmed: 21820080
Immunity. 2016 Sep 20;45(3):701-703
pubmed: 27653602
J Exp Med. 2012 Aug 27;209(9):1671-87
pubmed: 22908323
J Clin Oncol. 2015 Sep 1;33(25):2780-8
pubmed: 26014293
PLoS One. 2018 Nov 2;13(11):e0206223
pubmed: 30388137
J Immunol. 2008 Dec 15;181(12):8576-84
pubmed: 19050277
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Cancer Immunol Res. 2016 Dec;4(12):1001-1006
pubmed: 27908931
Cancer Immunol Immunother. 2011 Oct;60(10):1419-30
pubmed: 21644036
Cell. 2012 May 25;149(5):979-93
pubmed: 22608084
Oncotarget. 2017 May 31;8(60):102617-102639
pubmed: 29254276
Nat Genet. 2006 May;38(5):500-1
pubmed: 16642009
Cell Rep. 2013 Jan 31;3(1):246-59
pubmed: 23318258
Cell. 2017 Sep 7;170(6):1120-1133.e17
pubmed: 28803728
Nat Immunol. 2016 Jan;17(1):95-103
pubmed: 26523864
Med Res Rev. 2019 Jan;39(1):70-113
pubmed: 29785785
Gene Ther. 2012 Oct;19(10):988-98
pubmed: 22071969
Mol Ther. 2014 Jan;22(1):112-22
pubmed: 24025748
Oncol Lett. 2016 Sep;12(3):1941-1948
pubmed: 27588143
Immunity. 2007 Aug;27(2):281-95
pubmed: 17723218
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
PLoS One. 2011;6(6):e20598
pubmed: 21674047
PLoS One. 2010 Nov 15;5(11):e13984
pubmed: 21085593
Nat Commun. 2011;2:240
pubmed: 21407206
Clin Cancer Res. 2010 May 15;16(10):2861-71
pubmed: 20460488
J Exp Med. 2018 Apr 2;215(4):1091-1100
pubmed: 29511066
Cell Rep. 2018 Jul 17;24(3):607-618
pubmed: 30021159
Immunity. 2016 Aug 16;45(2):233-5
pubmed: 27533009
J Immunother. 2013 Nov-Dec;36(9):477-89
pubmed: 24145359
Nat Immunol. 2013 Mar;14(3):281-9
pubmed: 23334788
Science. 1993 Apr 23;260(5107):547-9
pubmed: 8097338
Sci Transl Med. 2014 Mar 5;6(226):226ra32
pubmed: 24598590
Immunity. 2012 Mar 23;36(3):374-87
pubmed: 22425248
Nat Immunol. 2013 Mar;14(3):271-80
pubmed: 23334789
Carcinogenesis. 1993 Nov;14(11):2353-8
pubmed: 8242866
Eur J Cancer. 2016 Jan;52:50-66
pubmed: 26645943
Exp Cell Res. 2011 Mar 10;317(5):620-31
pubmed: 21376175
Cell. 2015 Sep 10;162(6):1217-28
pubmed: 26321681
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
J Immunother Cancer. 2018 Dec 27;6(1):157
pubmed: 30587233
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Carcinogenesis. 2004 Sep;25(9):1771-8
pubmed: 15105299
Ann Surg Oncol. 2006 Aug;13(8):1078-84
pubmed: 16865590
Cancer Immunol Res. 2017 Jan;5(1):9-16
pubmed: 27941003
Eur J Immunol. 2005 Nov;35(11):3297-306
pubmed: 16220539
Science. 2013 Oct 11;342(6155):1242454
pubmed: 24115444
Cancer Res. 2011 Aug 15;71(16):5445-54
pubmed: 21708958
Blood. 2004 Apr 15;103(8):3065-72
pubmed: 15070686
Cancer Res. 2016 Jul 1;76(13):3684-9
pubmed: 27197182
Cancer Gene Ther. 2011 Mar;18(3):167-75
pubmed: 21102422
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
Trends Immunol. 2015 Apr;36(4):257-64
pubmed: 25773310
Cold Spring Harb Perspect Biol. 2010 Jan;2(1):a001008
pubmed: 20182602
Nat Biotechnol. 2004 Jan;22(1):70-7
pubmed: 14647305
PLoS Pathog. 2012 Sep;8(9):e1002913
pubmed: 22969431
Vaccines (Basel). 2016 Dec 06;4(4):
pubmed: 27929420
Biochim Biophys Acta. 1970 Dec 29;222(3):565-82
pubmed: 5496487
Mol Ther. 2012 Feb;20(2):298-305
pubmed: 22068428
Cancer Res. 2004 Sep 15;64(18):6684-92
pubmed: 15374985
Cell. 2018 Aug 9;174(4):1031-1032
pubmed: 30096300
Cancer Immunol Res. 2013 Oct;1(4):229-34
pubmed: 24777852
Cell Immunol. 2010;262(2):89-95
pubmed: 20236628
J Virol. 1992 Aug;66(8):4992-5001
pubmed: 1385835
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2729-34
pubmed: 19202079
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Cancer Res. 2017 Jul 15;77(14):3894-3907
pubmed: 28566332
J Exp Med. 2011 Mar 14;208(3):469-78
pubmed: 21339327
Cell. 2000 Mar 17;100(6):655-69
pubmed: 10761931
J Exp Med. 2015 Aug 24;212(9):1345-60
pubmed: 26261266
Cancer Gene Ther. 2012 Nov;19(11):757-66
pubmed: 22956041
Nat Biotechnol. 2019 Jan 3;37(1):12-17
pubmed: 30605149
J Immunol. 2008 May 1;180(9):5935-45
pubmed: 18424713
Clin Cancer Res. 2010 Jul 1;16(13):3485-94
pubmed: 20479064
Melanoma Res. 2016 Oct;26(5):429-41
pubmed: 27455380
Clin Transl Med. 2018 Nov 14;7(1):35
pubmed: 30426287
Immunology. 2017 Oct;152(2):175-184
pubmed: 28621843
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Immunity. 2011 Dec 23;35(6):871-82
pubmed: 22195744
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
J Immunother Cancer. 2018 May 16;6(1):36
pubmed: 29764498

Auteurs

Iris Scherwitzl (I)

Department of Pathology, NYU School of Medicine, New York, NY, USA.

Silvana Opp (S)

Department of Pathology, NYU School of Medicine, New York, NY, USA.

Alicia M Hurtado (AM)

Department of Pathology, NYU School of Medicine, New York, NY, USA.

Christine Pampeno (C)

Department of Pathology, NYU School of Medicine, New York, NY, USA.

Cynthia Loomis (C)

Department of Pathology, NYU School of Medicine, New York, NY, USA.

Kasthuri Kannan (K)

Department of Pathology, NYU School of Medicine, New York, NY, USA.

Minjun Yu (M)

Department of Pathology, NYU School of Medicine, New York, NY, USA.

Daniel Meruelo (D)

Department of Pathology, NYU School of Medicine, New York, NY, USA.

Classifications MeSH